Sodium–Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections
Authors: Chintan V. Dave, Sebastian Schneeweiss, Dae Kim, Michael Fralick, Elisabetta Patorno
Journal: Annals of Internal Medicine (2019)

Letters17 December 2019Sodium–Glucose Cotransporter-2 Inhibitors and Urinary Tract InfectionsChintan V. Dave, PharmD, PhD, Sebastian Schneeweiss, MD, ScD, Dae Kim, MD, MPH, ScD, Michael Fralick, MD, SM, and Elisabetta Patorno, MD, DrPHChintan V. Dave, PharmD, PhDBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (C.V.D., S.S., D.K., M.F., E.P.)Search for more papers by this author, Sebastian Schneeweiss, MD, ScDBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (C.V.D., S.S., D.K., M.F., E.P.)Search for more papers by this author, Dae Kim, MD, MPH, ScDBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (C.V.D., S.S., D.K., M.F., E.P.)Search for more papers by this author, Michael Fralick, MD, SMBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (C.V.D., S.S., D.K., M.F., E.P.)Search for more papers by this author, and Elisabetta Patorno, MD, DrPHBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (C.V.D., S.S., D.K., M.F., E.P.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L19-0671 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We appreciate Drs. Sarafidis and Papagianni's comment that lack of information on UTI history beyond the 6-month baseline period during which the exclusion criteria were ascertained may have caused unmeasured confounding in our study. As they note, this factor could contribute to the SGLT-2 inhibitor group having a lower rate for the outcome of UTIs than the glucagon-like peptide-1–receptor agonist group. In addition to patients who developed a UTI in the baseline period, our study excluded those with medical conditions that put them at higher risk for chronic UTIs (such as chronic glomerulonephritis and enlarged prostate) and thus ...Reference1. Puckrin R, Saltiel MP, Reynier P, et al. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018;55:503-14. [PMID: 29484489] doi:10.1007/s00592-018-1116-0 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (C.V.D., S.S., D.K., M.F., E.P.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M18-3136. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections Chintan V. Dave , Sebastian Schneeweiss , Dae Kim , Michael Fralick , Angela Tong , and Elisabetta Patorno Sodium–Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections Trisha Benjamin and Christie Schumacher Sodium–Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections Pantelis Sarafidis and Aikaterini Papagianni Metrics 17 December 2019Volume 171, Issue 12Page: 944-945KeywordsDatabasesDisclosureFactor analysisGenitourinary infectionsGlomerulonephritisHemoglobinMedical conditions ePublished: 17 December 2019 Issue Published: 17 December 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...